Regulatory T Cells in Ovarian Carcinogenesis and Future Therapeutic Opportunities

Cancers (Basel). 2022 Nov 8;14(22):5488. doi: 10.3390/cancers14225488.

Abstract

Regulatory T cells (Tregs) have been shown to play a role in the development of solid tumors. A better understanding of the biology of Tregs, immune suppression by Tregs, and how cancer developed with the activity of Tregs has facilitated the development of strategies used to improve immune-based therapy. In ovarian cancer, Tregs have been shown to promote cancer development and resistance at different cancer stages. Understanding the various Treg-mediated immune escape mechanisms provides opportunities to establish specific, efficient, long-lasting anti-tumor immunity. Here, we review the evidence of Treg involvement in various stages of ovarian cancer. We further provide an overview of the current and prospective therapeutic approaches that arise from the modulation of Treg-related tumor immunity at those specific stages. Finally, we propose combination strategies of Treg-related therapies with other anti-tumor therapies to improve clinical efficacy and overcome tumor resistance in ovarian cancer.

Keywords: cancer; chemotherapy; combination therapy; epigenetics; immunotherapy; ovarian cancer; regulatory T cells.

Publication types

  • Review